Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-024-02689-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Ami Jo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba, Iwate, 028-3695, Japan. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Immune Checkpoint Inhibitors, Neoplasm Recurrence, Local, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Doxorubicin + cisplatin and paclitaxel + carboplatin are standard chemotherapy regimens for endometrial cancer. The development of PD-1 and PDL-1 antibody drugs has led to the use of these agents for endometrial cancer in other countries. The KEYNOTE-775 trial for advanced or recurrent endometrial cancer demonstrated the benefits of pembrolizumab and lenvatinib combination therapy, and the results of this trial led to the approval of its coverage for recurrent cancer by the Japanese health insurance system. Currently, treatment with immune checkpoint inhibitors is transitioning from second-line to first-line therapy. In a global randomized phase III study, the drugs dostarlimab, durvalumab, and atezolizumab, which are not yet approved in Japan, showed better results in the study arms than in the control arm. Additionally, biomarkers have been developed for endometrial cancer, enabling gynecologists to pursue treatment options based on the biomarkers detected for better treatment outcomes. In this article, we review the clinical trials of immune checkpoint inhibitors for advanced or recurrent endometrial cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba, Iwate, 028-3695, Japan.
- Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba, Iwate, 028-3695, Japan. tshoji@iwate-med.ac.jp.
Zitieren
APA
Jo, A., Shoji, T., Otsuka, H., Abe, M., Tatsuki, S., Chiba, Y., Sato, S., Takatori, E., Kaido, Y., Nagasawa, T., Kagabu, M., & Baba, T. (2025). Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02689-8
Vancouver
Jo A, Shoji T, Otsuka H, Abe M, Tatsuki S, Chiba Y, et al. Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-024-02689-8
BibTeX
@article{Jo2025,
author = {Jo, Ami and Shoji, Tadahiro and Otsuka, Haruka and Abe, Marina and Tatsuki, Shunsuke and Chiba, Yohei and Sato, Sho and Takatori, Eriko and Kaido, Yoshitaka and Nagasawa, Takayuki and Kagabu, Masahiro and Baba, Tsukasa},
title = {Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-024-02689-8}
}
EUVIMED